8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: August 31, 2020

(Date of earliest event reported)

Commission file number 001-36440

AVANOS MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (844) 428-2667

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

Avanos Medical, Inc. (the “Company”) issued a press release on August 31, 2020, announcing that, effective that same day, Bill Haydon was appointed as Senior Vice President & General Manager – Pain Franchise of the Corporation. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered “filed” under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d)Exhibits.

The following exhibits are filed with this Current Report on Form 8-K:

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Document

Exhibit 99.1

Avanos Medical, Inc. Appoints Bill Haydon as Senior Vice President & General Manager, Pain Franchise

ALPHARETTA, Ga., Aug. 31, 2020 / PRNewswire / -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Bill Haydon has been appointed senior vice president & general manager for the company’s newly combined pain franchise. In this role, Haydon will spearhead a global strategy to support transformation and growth in this business. Previously, Haydon served as senior vice president and general manager for the medical division of Cantel, a leading provider of infection prevention products and services in the healthcare market.

Haydon brings to Avanos nearly 25 years of experience in strategy, marketing, commercialization, innovation, M&A strategy development and execution. While at Cantel, Haydon played an integral role in creating and leading the global marketing and business development organizations, restructuring the commercial organization, building a robust, market-driven product pipeline, and establishing a proactive, strategic approach to M&A. Prior to that, Haydon held global leadership roles at a number of high-growth organizations in the medical device and medical technology space, including Boston Scientific, Bayer Healthcare and St. Jude Medical.

“To improve focus, drive efficiencies and better serve our customers, we have united our Interventional Pain and Acute Pain businesses under one global pain franchise leader,” stated Joe Woody, chief executive officer. “This mirrors the structure of our Chronic Care organization and we expect this alignment to accelerate growth and allow us to capitalize on areas where our pain businesses overlap, like in our orthopedic and sports medicine channels. We are very pleased to have Bill join Avanos in this new role. His prior experience at Cantel in creating sustainable growth strategies and establishing a proactive, strategic approach to M&A will be of great value as we focus on creating long-term value for our customers, employees and shareholders.”

Haydon holds a bachelor’s degree from the University of Minnesota Duluth, and an MBA from the University of Minnesota’s Carlson School of Management.

About Avanos Medical, Inc.

Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients' quality of life. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands in more than 90 countries. For more information, visit Avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.